159 related articles for article (PubMed ID: 17893231)
1. Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover.
Prasad NK; Tandon M; Badve S; Snyder PW; Nakshatri H
Carcinogenesis; 2008 Jan; 29(1):25-34. PubMed ID: 17893231
[TBL] [Abstract][Full Text] [Related]
2. SHIP2 phosphoinositol phosphatase positively regulates EGFR-Akt pathway, CXCR4 expression, and cell migration in MDA-MB-231 breast cancer cells.
Prasad NK
Int J Oncol; 2009 Jan; 34(1):97-105. PubMed ID: 19082482
[TBL] [Abstract][Full Text] [Related]
3. Protein phosphatase 2A PR130/B''alpha1 subunit binds to the SH2 domain-containing inositol polyphosphate 5-phosphatase 2 and prevents epidermal growth factor (EGF)-induced EGF receptor degradation sustaining EGF-mediated signaling.
Zwaenepoel K; Goris J; Erneux C; Parker PJ; Janssens V
FASEB J; 2010 Feb; 24(2):538-47. PubMed ID: 19825976
[TBL] [Abstract][Full Text] [Related]
4. High expression of obesity-linked phosphatase SHIP2 in invasive breast cancer correlates with reduced disease-free survival.
Prasad NK; Tandon M; Handa A; Moore GE; Babbs CF; Snyder PW; Bose S
Tumour Biol; 2008; 29(5):330-41. PubMed ID: 19065064
[TBL] [Abstract][Full Text] [Related]
5. SH2-containing 5'-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent down-regulation of the epidermal growth factor receptor.
Prasad NK; Decker SJ
J Biol Chem; 2005 Apr; 280(13):13129-36. PubMed ID: 15668240
[TBL] [Abstract][Full Text] [Related]
6. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.
Sasaoka T; Wada T; Tsuneki H
Pharmacol Ther; 2006 Dec; 112(3):799-809. PubMed ID: 16842857
[TBL] [Abstract][Full Text] [Related]
7. The association between the SH2-containing inositol polyphosphate 5-Phosphatase 2 (SHIP2) and the adaptor protein APS has an impact on biochemical properties of both partners.
Onnockx S; De Schutter J; Blockmans M; Xie J; Jacobs C; Vanderwinden JM; Erneux C; Pirson I
J Cell Physiol; 2008 Jan; 214(1):260-72. PubMed ID: 17620296
[TBL] [Abstract][Full Text] [Related]
8. A novel oncogenic role of inositol phosphatase SHIP2 in ER-negative breast cancer stem cells: involvement of JNK/vimentin activation.
Fu CH; Lin RJ; Yu J; Chang WW; Liao GS; Chang WY; Tseng LM; Tsai YF; Yu JC; Yu AL
Stem Cells; 2014 Aug; 32(8):2048-60. PubMed ID: 24802135
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity.
Wada T; Sasaoka T; Funaki M; Hori H; Murakami S; Ishiki M; Haruta T; Asano T; Ogawa W; Ishihara H; Kobayashi M
Mol Cell Biol; 2001 Mar; 21(5):1633-46. PubMed ID: 11238900
[TBL] [Abstract][Full Text] [Related]
10. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation.
Zhuang G; Hunter S; Hwang Y; Chen J
J Biol Chem; 2007 Jan; 282(4):2683-94. PubMed ID: 17135240
[TBL] [Abstract][Full Text] [Related]
11. Dual role of SRC homology domain 2-containing inositol phosphatase 2 in the regulation of platelet-derived growth factor and insulin-like growth factor I signaling in rat vascular smooth muscle cells.
Sasaoka T; Kikuchi K; Wada T; Sato A; Hori H; Murakami S; Fukui K; Ishihara H; Aota R; Kimura I; Kobayashi M
Endocrinology; 2003 Sep; 144(9):4204-14. PubMed ID: 12933696
[TBL] [Abstract][Full Text] [Related]
12. SHIP2 multiple functions: a balance between a negative control of PtdIns(3,4,5)P₃ level, a positive control of PtdIns(3,4)P₂ production, and intrinsic docking properties.
Erneux C; Edimo WE; Deneubourg L; Pirson I
J Cell Biochem; 2011 Sep; 112(9):2203-9. PubMed ID: 21503961
[TBL] [Abstract][Full Text] [Related]
13. High SHIP2 expression indicates poor survival in colorectal cancer.
Yang J; Fu M; Ding Y; Weng Y; Fan W; Pu X; Ge Z; Zhan F; Ni H; Zhang W; Jin F; Xu N; Li J; Qiu L; Wang J; Gu X
Dis Markers; 2014; 2014():218968. PubMed ID: 25525286
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol 3,4,5-trisphosphate modulation in SHIP2-deficient mouse embryonic fibroblasts.
Blero D; Zhang J; Pesesse X; Payrastre B; Dumont JE; Schurmans S; Erneux C
FEBS J; 2005 May; 272(10):2512-22. PubMed ID: 15885100
[TBL] [Abstract][Full Text] [Related]
15. The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2.
Dyson JM; Kong AM; Wiradjaja F; Astle MV; Gurung R; Mitchell CA
Int J Biochem Cell Biol; 2005 Nov; 37(11):2260-5. PubMed ID: 15964236
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional profiling of C2C12 myotubes in response to SHIP2 depletion and insulin stimulation.
Huard C; Martinez RV; Ross C; Johnson JW; Zhong W; Hill AA; Kim R; Paulsen JE; Shih HH
Genomics; 2007 Feb; 89(2):270-9. PubMed ID: 17123777
[TBL] [Abstract][Full Text] [Related]
17. Membrane localization of Src homology 2-containing inositol 5'-phosphatase 2 via Shc association is required for the negative regulation of insulin signaling in Rat1 fibroblasts overexpressing insulin receptors.
Ishihara H; Sasaoka T; Ishiki M; Wada T; Hori H; Kagawa S; Kobayashi M
Mol Endocrinol; 2002 Oct; 16(10):2371-81. PubMed ID: 12351701
[TBL] [Abstract][Full Text] [Related]
18. The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase activity.
Vandeput F; Backers K; Villeret V; Pesesse X; Erneux C
Cell Signal; 2006 Dec; 18(12):2193-9. PubMed ID: 16824732
[TBL] [Abstract][Full Text] [Related]
19. Impact of the liver-specific expression of SHIP2 (SH2-containing inositol 5'-phosphatase 2) on insulin signaling and glucose metabolism in mice.
Fukui K; Wada T; Kagawa S; Nagira K; Ikubo M; Ishihara H; Kobayashi M; Sasaoka T
Diabetes; 2005 Jul; 54(7):1958-67. PubMed ID: 15983195
[TBL] [Abstract][Full Text] [Related]
20. Normalization of prandial blood glucose and improvement of glucose tolerance by liver-specific inhibition of SH2 domain containing inositol phosphatase 2 (SHIP2) in diabetic KKAy mice: SHIP2 inhibition causes insulin-mimetic effects on glycogen metabolism, gluconeogenesis, and glycolysis.
Grempler R; Zibrova D; Schoelch C; van Marle A; Rippmann JF; Redemann N
Diabetes; 2007 Sep; 56(9):2235-41. PubMed ID: 17596404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
